FindTrial
Sign In

Foscarnet

DRUG5 trials

Sponsors

Fondazione Gimema Franco Mandelli Onlus, Johns Hopkins Bloomberg School of Public Health, Shire, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Acquired Immunodeficiency SyndromeCytomegalovirus (CMV)Cytomegalovirus InfectionsCytomegalovirus RetinitisHIV InfectionsHematological DiseaseVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

Phase 2

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024
RecruitingCTIS2024-511627-34-00
Fondazione Gimema Franco Mandelli OnlusVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
Start: 2024-10-17Target: 31Updated: 2025-12-23

Phase 3

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
CompletedNCT00000136
Johns Hopkins Bloomberg School of Public HealthCytomegalovirus Retinitis, HIV Infections
Start: 1990-03-31End: 1991-10-31Updated: 2015-10-22
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
CompletedNCT00000134
Johns Hopkins Bloomberg School of Public HealthAcquired Immunodeficiency Syndrome, Cytomegalovirus Retinitis, HIV Infections
Start: 1992-12-31End: 1995-03-31Updated: 2015-09-14
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
CompletedNCT02931539
ShireCytomegalovirus (CMV)
Start: 2016-12-22End: 2020-08-17Updated: 2021-11-03

Phase 4

CMV-CTL for the Treatment of CMV Infection After HSCT
CompletedNCT03004261
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCytomegalovirus Infections, Hematological Disease
Start: 2016-11-30End: 2021-12-31Updated: 2023-04-25

Related Papers

Association Between Cytomegalovirus Viremia Clearance and Post-Solid Organ Transplant Mortality in Patients With Refractory Cytomegalovirus Infection: SOLSTICE Post Hoc Analysis.
2025-11-26
Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United States
Expert Review of Anti-infective Therapy2025-06-06
Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study
The Journal of Heart and Lung Transplantation2024-11-2812 citations
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
Blood2024-11-05
Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective
Journal of Medical Virology2024-04-018 citations
Maribavir: Mechanism of action, clinical, and translational science.
2024-01-0116 citations
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Clinical Infectious Diseases2023-11-2944 citations
S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
HemaSphere2023-08-01
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients
The Journal of Infectious Diseases2023-07-2869 citations
P16.38: Healthcare Resource Utilization in Transplant Recipients With Cytomegalovirus Infection Refractory to Prior Treatment With/Without Resistance Receiving Maribavir Versus Investigatorassigned Therapy: Exploratory Analysis of the Phase 3 SOLSTICE Trial
Transplantation2022-09-01
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Clinical Infectious Diseases2021-12-01275 citations
21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
Open Forum Infectious Diseases2021-11-011 citations
Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
The Journal of Clinical Pharmacology2019-08-0611 citations
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
Clinical Infectious Diseases2018-10-03212 citations